Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

(2021) Nikhil Patkar et al.   LEUKEMIA

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

(2021) Bruno Paiva et al.   LEUKEMIA

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia

(2021) Jean Philippe Vial et al.   Cancers

Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1)

(2021) Lei Shang et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Database-Guided Analysis for Immunophenotypic Diagnosis and Follow-Up of Acute Myeloid Leukemia With Recurrent Genetic Abnormalities

(2021) Carmen-Mariana Aanei et al.   Frontiers in Oncology

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

(2020) Ludovic Lhermitte et al.   MODERN PATHOLOGY

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

(2020) Nicholas J. Short et al.   JAMA Oncology

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

(2020) Abhishek Maiti et al.   AMERICAN JOURNAL OF HEMATOLOGY

Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML

(2020) Evgeny Klyuchnikov et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance

(2019) Jing-Ni Sui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Can we incorporate MRD assessment into clinical practice in AML?

(2019) Gert Ossenkoppele et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes

(2019) Anna Elinder Camburn et al.   PATHOLOGY

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia

(2019) Giovanni Rossi et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Detection and management of acute myeloid leukemia measurable residual disease

(2019) Giovangiacinto Paterno et al.   CURRENT OPINION IN HEMATOLOGY

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

CD7 is expressed on a subset of normal CD34-positive myeloid precursors

(2018) Katharina Kriegsmann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

(2018) S. Haubner et al.   LEUKEMIA

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

(2018) Francesco Buccisano et al.   Cancers

Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization

(2018) Gerrit J Schuurhuis et al.   Expert Review of Hematology

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings

(2014) W. Cui et al.   International Journal of Laboratory Hematology

Tumor heterogeneity makes AML a “moving target” for detection of residual disease

(2013) W. Zeijlemaker et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease

(2012) Giovanni Rossi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

(2011) Gert J. Ossenkoppele et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence, Sensitivity, and Specificity of Leukemia-Associated Phenotypes in Acute Myeloid Leukemia Using Specific Five-Color Multiparameter Flow Cytometry

(2008) Adhra Al-Mawali et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY